Tags : 5%

Novartis Acquires Worldwide Rights of Takeda’s Xiidra (lifitegrast ophthalmic solution)

Tuba Khan May 9, 2019

Shots: Takeda to receive $3.4B upfront with 1.9B milestones, making a total deal value of $5.3B. Novartis to get WW rights of Xiidra and will take ~400 employees associated with […]readmore

Tags : 5%

Novartis Acquires Worldwide Rights of Takeda’s Xiidra (lifitegrast ophthalmic solution)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : 5%

﻿Novartis Acquires Worldwide Rights of Takeda’s Xiidra (lifitegrast ophthalmic solution)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Novartis Acquires Worldwide Rights of Takeda’s Xiidra (lifitegrast ophthalmic solution)